Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00213798 | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients | completed | N/A | 200 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY |
| 15 |
| Dec 22, 2025 |
| clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07057531 | Tubeless VATS for Lung Cancer Surgery | completed | N/A | 73 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04965090 | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT05846594 | A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer(L1st) | completed | N/A | 463 | Hoffmann-La RocheINDUSTRY | 4 | Dec 17, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT06004167 | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT07267247 | Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer | completed | — | 100 | Taichung Veterans General HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03926260 | Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA(ELUCID) | completed | N/A | 100 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05664971 | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 119 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04583046 | Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation | completed | N/A | 78 | Yonsei UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06548451 | Augmented Reality Assisted Lung Nodule Localization: a Multicentered, Prospective, Randomly Controlled, Non-inferiority Trial | completed | N/A | 270 | Shanghai Chest HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02568553 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07250360 | Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC | completed | — | 2,072 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03132532 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04500535 | A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy(LIST) | completed | — | 535 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04614129 | Lung Cancer Risk and Early Detection in Firefighters | completed | N/A | 734 | Massachusetts General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06145750 | Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer(FIRSTLUNG) | completed | N/A | 28 | Delfi Diagnostics Inc.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07243899 | Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy | completed | — | 3,000 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT05339022 | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT05824273 | The INSPIRE-Lung Study | completed | N/A | 512 | Hackensack Meridian HealthOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02197234 | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | completed | Phase 1 | 52 | AstraZenecaINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT02606149 | Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life(HIPPOCRATE) | completed | N/A | 123 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05472532 | Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)(INOVOLINE) | completed | N/A | 101 | Hospices Civils de LyonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 22, 2025source: clinicaltrials